Prostate cancer patients who receive hypofractionated radiation therapy report consistent quality of life before and after treatment
The phase I/II trial enrolled 343 patients with low-to-intermediate risk prostate cancer at five institutions from 2002 to 2010 to study the effectiveness of HPFX RT, as well as the patients’ ability to tolerate the treatment. …